Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance in Premenopausal Women
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Effect of intravenous iron substitution (iron carboxymaltose (Ferinject®), total dose 15 mg/
kg (maximal dose: 1000mg) in 250 ml 0.9 % NaCl; intravenous infusion in 20 min)in non-anemic
premenopausal women with iron deficiency on
Primary objective:
- Mitochondrial capacity (Phosphocreatine Recovery rate assessed by 31P-MR-spectroscopy of
the lower leg muscle)
Secondary objectives:
- Maximal oxygen uptake during a graded cycling exercise test and time to exhaustion at
submaximal power during a constant-load cycling exercise test
- Plantarflexor muscle fatiguability as assessed by isokinetic dynamometry
- Trial with medicinal product